Dr. Sergio Quezada is a group leader at the UCL Cancer Institute in London where he heads the Immune Regulation and Tumour Immunotherapy Laboratory.
Prior to this Dr. Quezada worked with Dr. James Allison at Memorial Sloan-Kettering Cancer Center studying the mechanisms governing anti-tumour T-cell immunity, and how these mechanisms can be manipulated for the generation of potent anti-tumour immune responses.
Dr. Quezada’s research interest at UCL focuses on the study of the mechanism of action of anti-CTLA-4, anti-PD-1 and other immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways (including ICOS, 4-1BB, OX-40). His group has particular interest in the impact of immune-modulatory antibodies in the fate and function of tumour reactive CD4+ T cells and the role that the tumour microenvironment plays in the response and resistance to such therapies.
Dr Quezada is a Cancer Research UK Career Development fellow and the recipient of a Cancer Research Institute investigator Award.